×

Diagnosis & Therapy

Neoadjuvant atezolizumab shrinks NSCLC tumors

Neoadjuvant atezolizumab shrinks NSCLC tumors

Neoadjuvant atezolizumab shrinks NSCLC tumorsBY CHRISTINE KILGORE MDedge News SAN FRANCISCO – One-fifth of patients with resectable non–small cell lung cancer had a major pathologic response to neoadjuvant therapy with the immune checkpoint inhibitor atezolizumab...

read more

Continue Reading


Biomarkers


+

Prevention


+

Cost And Coping


+

Diagnosis and Therapy


+

Patient Journey


+